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Abstract
Proliferation of draining lymphatic vessels coupled with dynamic changes in lymph node volume and flow are
characteristic features in rheumatoid arthritis (RA). Furthermore, impaired lymph egress from inflamed synovium is
associated with joint flare in murine models of inflammatory-erosive arthritis. Unfortunately, advances towards a
greater understanding of lymphatic changes in RA pathogenesis have been slow due to the absence of outcome
measures to quantify lymphatic function in vivo. While lymphoscintigraphy is the current standard to assess
lymphedema and sentinel lymph nodes in cancer patients, its sensitivity and specificity are inadequate to study
lymphatics in RA. The emergence of high-resolution MRI, power Doppler ultrasound, and near-infrared imaging that
permits real-time quantification of lymphatic function in animal models has been a major advance, and these
techniques have produced a new paradigm of altered lymphatic function that underlies both acute arthritic flare
and chronic inflammation. In acute flare, lymphatic drainage increases several fold, whereas no lymphatic
contractions are detected in lymph vessels draining chronic arthritic joints. Moreover, these outcomes are now
being adapted to study lymphatics in RA towards the development of novel biomarkers of arthritic flare and the
discovery of new therapeutic targets. In particular, interventions that directly increase lymphatic egress from
diseased joints by opening collateral lymphatic vessels, and that restore lymphatic vessel contractions, provide
novel therapeutic approaches with potential for minimal toxicity and immunosuppression. To summarize the
origins of this field, recent advances, and future directions, we herein review: current knowledge of lymphatics in
RA based on classic literature; new in-vivo imaging modalities that have elucidated how lymphatics modulate acute
versus chronic joint inflammation in murine models; and how these preclinical outcome measures are being
translated to study lymphatic function in RA inflammation and how effective RA therapies alter lymphatic flow and
lymph nodes draining flaring joints.
Trial registration: ClinicalTrials.gov NCT02680067. Registered 7 December 2015; ClinicalTrials.gov NCT01098201.
Registered 30 March 2010; and ClinicalTrials.gov NCT01083563. Registered 8 March 2010.
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Background
Rheumatoid arthritis (RA) is a chronic, debilitating dis-
ease affecting over 1 million people in the United States,
and 1 % of the population worldwide [1]. In the current
etiological paradigm, autoimmunity to citrullinated pep-
tides drives a systemic inflammatory response that is
expressed most strongly in the joints, although a range
of other tissues can be affected. However, this model
does not explain the events that drive episodic occur-
rences, known clinically as arthritic or rheumatic flares,
and remissions, a hallmark of this disease. RA can also
be viewed as a multifactorial syndrome that arises from
an interaction of predetermined and stochastic factors
which foster disease onset and persistence [2]. This per-
spective highlights the major unmet clinical burden
shouldered by up to 30 % of RA patients refractory to
current therapies, and by the larger population that suf-
fers from sudden exacerbation of joint pain which may
be accompanied by aggressive cartilage and bone catab-
olism. Although ubiquitously used in both clinical and
preclinical studies [3–5], characterizing the term “flare”
has been challenging; however, current efforts are under-
way to create a uniform set of parameters to define RA
flare [6]. What is widely accepted is that flare can occur
in newly diagnosed RA patients or in patients with long-
standing, chronic arthritis. It is important to note that
these enigmatic flares often appear in the setting of
long-term effective therapy, sometimes without detect-
able changes in systemic inflammatory status as mea-
sured by inflammatory markers. To better understand
whether local factors can trigger arthritic flare, investiga-
tors turned their attention to lymphatic drainage, and
demonstrated that changes in lymphatic vessel structure
and function may be instrumental in provoking joint in-
flammation [7, 8]. These discoveries were facilitated by
novel imaging methods that provided quantitative as-
sessment of lymphatic vessel function for the first time.
These advances provide new opportunities to under-
stand how lymphatic biomarkers may be applied to aid
in diagnosis of arthritic flare and to assess therapeutic
effectiveness. The mechanistic pathways that maintain
lymph flow provide new therapeutic targets which may
restore dysfunctional lymphatics. In this review, we will:
outline the current knowledge of lymphatic function as
it relates to RA; describe how contemporary lymphatic
imaging methods reveal a central role for lymphatics in
arthritic flare; and point out the diagnostic and thera-
peutic potential of emerging lymphatic vessel biomarkers
in RA.
Lymphatic vasculature structure and function
It is important to understand normal lymphatic vascula-
ture anatomy in order to appreciate when lymphatic
dysfunction occurs. A primary purpose of the lymphatic
vasculature is to preserve fluid homeostasis within an or-
ganism [9]. Lymphatic vessels allow for reabsorption of
extravascular and interstitial fluid via blind-ended
lymphatic capillaries that become more organized col-
lecting lymphatic vessels. These vessels can drain to
lymph nodes (LNs) and are termed afferent vessels.
Collecting vessels that drain lymph from a LN are
termed efferent vessels. In humans, most of the vessels
and LNs in this network ultimately reach the thoracic
duct, which collects the lymph and drains it into the
blood circulatory system via the left subclavian vein. A
small portion of lymph fluid is collected by the right
lymphatic duct, which reaches the blood circulation via
the right subclavian vein [10]. Most mammals, including
mice and rats, have a similar anatomy—that is, thoracic
duct drainage of lymph into the blood vasculature
[11]—and thus are useful preclinical disease models.
Lymph movement results from multiple mechanisms in-
cluding intrinsic contraction of collecting vessels, as well
as the presence of valves in collecting vessels that pre-
vent retrograde movement and thus promote forward
movement of lymph. Lymph movement also occurs via
an intrinsic contraction associated with movement of
lymph as boluses; the mechanisms underlying and regu-
lating this contractile activity remain unclear and are an
area of intense study.
Mechanisms of lymphangiogenesis in inflammation
Research did not focus on the development and growth
of lymphatic vessels until the mid-1990s. Initial discover-
ies by Alitalo and colleagues found vascular endothelial
growth factor receptor 3 (VEGFR-3) as a marker for
lymphatic vessels in mouse and human tissue, and lent
credence to the theory of a venous origin for lymphatic
tissue; shortly thereafter, further research from the group
identified VEGF-C as the specific ligand for VEGFR-3
[12, 13]. Work from our group further delineated the
mechanism of lymphangiogenesis in inflammatory arth-
ritis [14–16]. In the tumor necrosis factor-transgenic
(TNF-Tg) mouse, we found increased expression of
VEGF-C and increased lymphatic vessel formation in
the synovium of these mice early on during the disease
process. At 2.5 months old, when clinical parameters
such as paw swelling are beginning, the TNF-Tg mice
were treated with VEGFR-3 blocking antibody to inhibit
VEGF-C binding. After 8 weeks of treatment, we noted
decreased lymphatic vessel formation and popliteal
lymph node (PLN) size, and increased evidence of joint
inflammation as determined by synovial volumes and
synovial inflammatory areas at the ankle and knee joints.
These findings led us to conclude that VEGF-C-induced
lymphangiogenesis ameliorates joint tissue damage in
arthritis by promoting drainage of inflamed joints.
Furthermore, our in-vitro studies showed that TNF
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stimulates osteoclast precursors to express VEGF-C and
promote lymphangiogenesis. However, persistent inflam-
mation may inhibit lymphatic vessel development and
draining function. Recently, we found that TNF stimulates
lymphatic endothelial cells to produce iNOS, which
inhibits lymphatic smooth muscle cell contraction and
lymph drainage [17]. An early study by Polzer et al. [18]
reported that specific blockade of TNF was associated
with increased lymphangiogenesis in a TNF-Tg mouse
model and in RA and spondyloarthritis synovial tissues,
suggesting a parallel mechanism in human disease [18].
They theorized that formation of more lymphatic ves-
sels would improve clearance of pathogenic media-
tors, including proinflammatory cytokines and effector
immune cells, such as macrophages. It should be
noted that they used a different model of the TNF-Tg
mouse, which develops severe inflammatory disease
earlier than our model. The finding that both TNF
and TNF inhibition can stimulate lymphangiogenesis,
although counterintuitive, may therefore relate to the
location, stage, and extent of inflammation. It is clear,
however, that further research will be necessary to clarify
the role of TNF in lymphangiogenesis and inflammation.
Lymphatics in RA
Although Chauffard and Ramond first described LN in-
volvement and lymphadenopathy in RA patients in 1896
[19, 20], remarkably little is still known about the patho-
logic features and underling etiology. Harold Paulus and
colleagues proposed that effector lymphocytes in lymph-
atic fluid were central to RA pathogenesis. In support of
this view was the dramatic improvement of joint symp-
toms in RA patients who underwent drainage of the
thoracic duct [21]. They described a cohort of nine
women with untreated RA aged 24–65 years old who
underwent insertion of a fistula into the thoracic duct
and drainage of lymphatic fluid. Cells were removed
from the fluid and reinfused; the depletion was per-
formed daily for 19–105 days. Within 1 week, the inves-
tigators documented improvement in the number of
tender and swollen joints, decreased morning stiffness,
and improved grip strength. Unfortunately, symptoms
returned after removal of the fistula and completion of
the study. In subsequent experiments they infused au-
tologous labeled lymphocytes, and arthritic flares were
noted a mean of 3.5 days after administration. These
findings supported their hypothesis that lymphocytes in
the lymphatic fluid are the primary mediators of RA
[22–24]. Despite the new knowledge gained in these
studies, further advances using this approach were
stalled due to the lack of visual and quantitative assess-
ments coupled with the challenges related to the feasibil-
ity of the procedure and transient responses. Indeed, the
entire literature on lymphatic outcomes in arthritis is
limited to three peer-reviewed publications from 1937 to
2001 [25–27].
Classical lymphoscintigraphy imaging of arthritis in the
clinic
Historically, performance of lymphoscintigraphy in arth-
ritis patients was limited to those with lymphedema. In
1968, Kallioma and Vastamak [28] reported on lymphos-
cintigraphy studies in Finland of the lymphatics in two
women with RA who subsequently developed lymph-
edema of the right arm. They noted decreased uptake in
the axillary nodes of the lymphedematous arthritic hand
at both timepoints, and proposed an association between
lymphatic dysfunction and inflammatory arthritis. Subse-
quently, radiocolloid lymphoscintigraphy became the
imaging modality of choice over the lymphogram, an in-
vasive procedure that requires cannulation and injection
of lymphatic vessels with contrast in order to visualize
them with X-ray imaging [29].
In the 1990s, several studies used 99technetium (99Tc)
colloid lymphoscintigraphy to demonstrate lymphatic
dysfunction in patients with RA or psoriatic arthritis who
developed lymphedema in their arthritic extremities
[30–33]. In the majority of these case reports, lymphedema
lessened when arthritis improved after therapy; this was as-
sociated with normalization of colloid uptake assessed by
lymphoscintigraphy. However, improvement was not asso-
ciated with the duration of lymphedema, arthritis, or the
type of disease-modifying anti-rheumatic drug (DMARD).
The co-occurrence of RA and lymphedema is a relatively
rare event so opportunities to gain additional insights are
limited; gaining more understanding of the role of lym-
phatics in RA requires an alternative strategy.
In our initial human studies we turned to lymphoscin-
tigraphy to analyze lymphatic transport in RA inflamma-
tion pre and post anti-TNF therapy as part of a clinical
study (ClinicalTrials.gov NCT01083563). The duration
of treatment was 18 weeks, and patients were scanned
just prior to initiation of therapy and after 18 weeks. An
example of these 99Tc sulfur colloid tracing studies is
shown in Fig. 1. Colloid was injected in the usual fashion
into the web spaces of the fingers or toes by a radiolo-
gist, and the limb was scanned at specific timepoints.
Because lymphoscintigraphy cannot identify individual
lymphatic vessels, it cannot detect lymphatic contrac-
tions. The technique therefore relies on the transit time
(tt) of colloid from the injection site to LN regions, and
compares the tt with known normal times. This study
produced interesting findings, but we abandoned this
approach due to the relatively invasive nature of the
technique, radiation exposure, and the prolonged dur-
ation of the procedure; these considerations limit its use
in the long-term, large-scale studies necessary to further
understand the role of lymphatic flow during flare.
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Contrast-enhanced MRI of draining LNs
MRI in animal models
To formally address the barriers of real-time in-vivo im-
aging of lymphatics in RA patients, we turned to contrast-
enhanced (CE) MRI to assess the natural history of
inflammatory-arthritis in the TNF-Tg and K/BxN murine
models of inflammatory-erosive arthritis [34–36]. Al-
though MRI methods to assess synovial inflammation in
arthritis were well established [37], visualization of lym-
phatics was never documented. Subsequent CE-MRI stud-
ies in TNF-Tg (3647 line) mice revealed that the draining
LN undergoes dynamic transitions which are associated
with activity of the arthritis in the proximal joint [38–40].
In the initial “expanding” phase, lymphatic fluid flows at
an increased rate and volume from an affected joint to the
draining LN via afferent lymphatic vessels. The LN vol-
ume expands, presumably to accommodate the influx of
cells and lymph exiting the inflamed synovium. Further-
more, a subset of B cells, termed B-cells-in-inflamed-
nodes (B-in cells), accumulates in follicular areas of the
draining LN [41, 42]. Following an extended expanding
phase (typically from 3 to 6 months of age in this model),
a stochastic event leads to asymmetric “collapse” of the
LN and lymphatic vessels in series along the ipsilateral
axis [42, 43]. Coincident with the collapse, B-in cells trans-
locate to the paracortical sinuses of the LN, the proximal
joint swells, and joint histopathology shows synovitis.
Additionally, intravital immunofluorescent microscopy
studies pre and post treatment with anti-CD20 antibodies
that ameliorated arthritic inflammation in TNF-Tg mice
demonstrated that translocated B-in cells effectively block
passive lymph flow through the LN. Further support of
the important function of the B-in cells was the restor-
ation of lymphatic flow by B-cell depletion therapy [38].
Interestingly, while B-cell depletion allowed for restoration
of passive flow and amelioration of synovial inflammation,
it did not restore the lymphatic contractions or active
lymphatic transport. Thus, B cells play a passive role in an
arthritic flare that lessens in severity when passive lymph-
atic egress from inflamed joints occurs. This finding sug-
gested two novel intervention strategies currently under
investigation: treatment with agents that restore lymphatic
contraction and active lymphatic flow; and nonimmuno-
suppressive treatments that open collateral lymphatic ves-
sels to restore local lymphatic egress by circumventing the
sites of B-cell obstruction. A third concept arising from
these studies focused on the involvement of lymphatic
smooth muscle cells in dysfunction of lymphatics in RA
inflammation. Molecular mechanisms responsible for im-
paired lymphatic smooth muscle cells and their progeni-
tors/stem cells in RA are another active research focus.
MRI in clinical studies
To test whether RA pathogenesis also involves expand-
ing and collapsed draining LNs, we completed a clinical
pilot study in which patients with knee flare were im-
aged with CE-MRI pre and post certolizumab (CZP)
therapy (ClinicalTrials.gov NCT01098201). Consistent
with the natural history of inflammatory-erosive arthritis
in murine models, 2D CE-MRI of patients with newly
diagnosed RA who had a flare was associated with highly
vascular knee synovitis, bone marrow changes, and very
large “expanded” PLN (Fig. 2a). The 3D rendering for
volumetric analyses confirmed this finding (Fig. 2b). In
contrast, 2D MRI of patients with chronic arthritis (dis-
ease duration > 20 years) who developed a flare revealed
end-stage synovitis adjacent to focal bone erosions and
tiny PLN (Fig. 2c). Volumetric analysis confirmed the
predicted “moth-eaten” appearance of the synovium,
where vascularity and perfusion is compromised by
interdigitating necrotic pannus tissue, and “collapsed”
PLN (Fig. 2d). Quantitatively, the total LN volume in 7
of 10 patients with measurable LN on CE-MRI de-
creased 16 weeks after CZP therapy (mean decrease
Fig. 1 Increased lymphatic flow from flaring joints normalizes with
effective anti-TNF therapy. Images of 99Tc sulfur colloid tracing of
the lower extremity to the pelvis obtained from a RA patient with
asymmetric knee flare enrolled in a clinical study to assess the effects
of anti-TNF therapy on arthritis and lymphatics (ClinicalTrials.gov
NCT01083563). Note the bright 99Tc sulfur colloid signal in the
inguinal (arrows) and popliteal (arrowheads) areas on both lower
extremities pre treatment, and the decreased signal post treatment,
which resulted in normalization of the tt from 15 minutes to
60 minutes. Schematic diagram between the lymposcintigrams
orients the regions of interest. R right leg, L left leg
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37 %; p < 0.002). Significant improvement in knee pain
measured by the Rheumatoid and Arthritis Outcome
Score for the knee [44] inversely correlated with de-
crease in PLN volume (R2 = 0.94). Collectively, these data
indicate that RA patients who sustain draining LN vol-
ume during anti-TNF therapy experienced the greatest
pain relief in flaring joints, and provide the first clinical
evidence to support the concept that dynamic changes
in LN volume correlate with response to therapy in RA.
MRI of lymphatics as biomarkers
Based on the aforementioned preclinical and clinical
studies, there is reasonable evidence to support the use
of MRI in evaluating draining LNs as a potential early
marker of arthritic flare. While the murine models of
arthritis have more fully defined that collapse of a drain-
ing LN is associated with arthritic flare, a similar correl-
ation in humans has yet to be elucidated. We know, for
example, that LNs undergo dramatic changes during
synovial inflammation [45], and that these changes can
differentiate between RA versus osteoarthritis. How-
ever, MRI alone cannot currently evaluate lymphatic
vessels, which may be a potential limitation of this
imaging modality.
Power Doppler ultrasound
MRI is the gold standard for quantitative deep soft-tissue
imaging due to its unparalleled sensitivity, specificity, and
clinical validation [46, 47]. However, the prohibitively high
costs of MRI and limited access have contributed to a
marked increase in ultrasound (US) imaging. US has sev-
eral advantages including real-time imaging, accessibility,
cost-efficiency, and absence of ionizing radiation [48].
Moreover, US is particularly useful for assessment of RA
joint inflammation with gray-scale imaging, and power
Doppler (PD) US assessment of synovial hyperemia; both
modalities assist in the diagnosis of active synovitis and
flares while providing semiquantitative analyses (PD
Score) of synovial inflammation for clinical research
[49–52]. MRI cost-efficiency issues also apply to pre-
clinical research [53–56], so we adapted PD-US im-
aging to murine models of inflammatory-erosive
arthritis to assess synovitis and alterations of draining
LNs longitudinally. Recently, we validated our PD-US
Fig. 2 Expanding versus collapsed popliteal LNs in early versus late-stage RA knee flare. MRIs were obtained from RA patients with new-onset
(a,b) and long-standing (>20 years) (c,d) asymmetric knee flare, who were enrolled in a phase 4 clinical trial to assess the effects of anti-TNF
therapy on PLN volume (ClinicalTrials.gov NCT01098201). The 2D sagittal views (a,c) and 3D volume renderings (b,d) illustrate the dramatic
differences between early RA flare with expanded PLN (pink, green and yellow arrows corresponding to pseudocolored PLN) adjacent to highly
inflamed synovium and focal erosions in the lateral femoral condyle (*), compared with the barely visible collapsed PLN (blue and yellow arrows
corresponding to pseudocolored PLN) adjacent to advanced pannus tissue and extensive bone erosions
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quantitative assessments of expanding vs collapsed
PLN in TNF-Tg mice [57, 58]. However, PD-US im-
aging of human LN, particularly PLN, remains elusive
due to tissue depth concerns, and continues to be an
area of active investigation.
Near-infrared imaging of indocyanine green
The availability of near-infrared (NIR) imaging of
injected indocyanine green (ICG) fluorescent dye was a
transformative advance in the quantitative assessment of
in-vivo lymphatic function. Low-resolution NIR-ICG im-
aging has been used to identify sentinel LN during
tumor resection surgery for a decade [59, 60], but appro-
priate optics with computer analyses to quantify human
lymphatic function was introduced only recently. In
these pioneering studies, groups such as that of Sevick-
Muraca and colleagues applied NIR-ICG imaging tech-
niques to evaluate lymphatic vessels in patients with
lymphedema [61–63]. More recently, they examined 24
patients with lymphedema and 20 healthy controls, and
demonstrated more tortuous and friable lymphatic
vessels with extravascular accumulation of lymph in
lymphedema patients compared with controls [64]. Fur-
thermore, they quantified the contraction rate of the in-
trinsic contractile activity of lymphatic vessels in healthy
patients. However, they were unable to calculate the
contraction rate in lymphedema patients due to the dys-
morphic vessel architecture and the inability to visualize
ICG-labeled lymph movement in bolus formation, which
is how the lymphatic contractions are quantified. More-
over, NIR-ICG imaging actually showed some retrograde
movement of lymph in the lymphedema patients. This
finding is likely due to the loss of normal vessel con-
tractile ability followed by extravasation of lymph into
the surrounding tissue and chronic tissue edema in these
patients. A major question we plan to address is whether
disturbances in RA lymphatic function are analogous to
those observed in lymphedema patients.
The first publication describing NIR-ICG imaging in
arthritis used infrared spectroscopy to study synovial
fluid in patients with inflammatory arthritis versus
osteoarthritis in order to differentiate the types of arth-
ritis [65]. Preclinical studies using mouse models of arth-
ritis reported that in-vivo arthritis detection in the early
stages of disease activity is feasible with the use of NIR
imaging and fluorescent-labeled molecules such as ICG
and folate receptor-targeted dyes [66–68]. Moving to-
wards clinical translation, Krohn et al. [69] examined the
hands of 31 patients with untreated early RA using NIR-
ICG optical imaging versus conventional MRI and US.
Patients were given intravenous ICG and were assessed
with a specialized imaging system and camera. They
examined wrist, metacarpophalangeal (MCP), and
proximal interphalangeal (PIP) joints and developed a
4-point scoring system to identify the degree of en-
hancement. The findings were correlated with MRI
scoring of synovitis in the same joints. The results
showed that NIR-ICG imaging correlates well with
MRI findings at certain phases of ICG uptake, but it
was inconsistent and not superior to current imaging
modalities. However, the relative speed and simplicity
of this minimally invasive procedure coupled with in-
vivo real-time results demonstrated the potential of
providing information to the clinician in a timely
manner.
We are now performing a clinical pilot study of NIR-
ICG imaging of the upper extremities in RA patients ex-
periencing hand and/or wrist joint flares, and comparing
the lymph flow data with that observed in healthy
controls, to evaluate lymphatic vasculature and LNs in
human subjects (ClinicalTrials.gov NCT02680067). In
brief, a custom NIR imaging system is used to visualize
lymphatic contractions after a negligible amount of ICG
dye is injected into the web spaces of the hands. NIR ex-
citation is monitored using a power meter. After the in-




Fig. 3 Clinical NIR imaging to quantify lymphatic flow in the upper extremity. A custom NIR imaging system (FD-1665; FluxData Inc., Rochester,
NY, USA) was used to assess lymphatic contraction frequency in a healthy human subject after ICG injection in the second, third, and fourth web
spaces of both hands as described in ClinicalTrials.gov NCT2680067. NIR excitation (<1.8 mW/cm2) was monitored with a Thorlabs PM16-121
power meter adjacent to the first web space. After injections, the upper extremities were imaged for 10 minutes to observe lymphatic flow.
Visible and NIR (>800 nm) images were collected simultaneously; ICG fluorescence images were used to pseudocolor the visible image to provide
anatomic localization (a). The ROI was positioned over lymphatics to calculate the mean pixel value for each NIR frame; peaks associated with
lymphatic contractions were counted to calculate cpm. Representative images of the left hand (b) obtained from real-time video (Additional file 1:
Movie 1) and right antecubital fossa (c) (Additional file 2: Movie 2) with the ROI and the respective cpm (green)
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for 10 minutes to observe lymphatic flow. A region of
interest (ROI) is then positioned over lymphatics to cal-
culate the mean pixel value; peaks associated with
lymphatic contractions are indicative of contractions per
minute (cpm). Figure 3 and Additional file 1: Movie 1
and Additional file 2: Movie 2 describe the technique
and illustrate the sensitivity and specificity of the ap-
proach to quantify lymphatic contractions using this
first-generation experimental approach.
The rationale for using NIR-ICG to evaluate lymphatic
contractions is reasonable because it provides real-time
information for the clinician. Furthermore, dysfunctional
contractions, or no contractions, could indicate that the
arthritic episode is the result of a drainage issue rather
than synovial disturbances. The treatment would thus be
tailored appropriately (i.e. with use of anti-TNF therapy),
which has been associated with increased lymphatic
angiogenesis [18] rather than DMARDs or steroids.
Because of the extensive use of ICG in cardiovascular
imaging over the decades, this dye has been studied
extensively in humans and has been approved by the
FDA for use as an imaging dye. There is therefore no
major health limitation of the NIR-ICG technique. The
only limitation is the duration of a study, which can take
about 1–2 hours, the equivalent of current imaging tech-
niques such as MRI.
Conclusions
The potential importance of lymphatic function as a
key variable in RA flare is supported by the presence of
palpable LN and lymphedema in some patients, and by
preclinical data demonstrating major alterations in
draining LNs and vasculature prior to arthritis onset.
The role of the lymphatics in RA can now be examined
with the advent of in-vivo imaging modalities that
quantify lymphatic flow and contraction frequency.
These technical advances may empower investigators to
promote understanding in three critical areas. The first
area is the redefinition of patterns of lymphatic flow
anatomically, because most of our knowledge is derived
from cadaveric studies and circulatory system mapping.
Interestingly, our early studies have demonstrated in-
consistencies in lymphatics drainage compared with
previously published data. The second area is discovery
of the cellular, molecular, and structural mechanisms
that regulate lymphatic function and that are closely
integrated with local biomechanics, inflammation, and
parasympathetic innervation. Finally, the ultimate goal
of this research is to identify novel molecular targets
that will give rise to new interventions for RA flare. To
achieve this goal, advancing technologies to noninva-
sively evaluate superficial and deep lymphatics in
humans is a critical first step.
Additional files
Additional file 1: Video 1 of the left hand of a healthy patient after
injection of ICG into the web spaces. The synchronized chart below is
the mean fluorescent intensity (arbitrary units) within the green ROI. 20×
real time. (M4V 2.64 mb)
Additional file 2: Video 2 of the right arm of a healthy patient after
injection of ICG into the web spaces. The synchronized chart below is
the mean fluorescent intensity (arbitrary units) within the green ROI. 20×
real time. (M4V 2.18 mb)
Acknowledgements
HR is supported by grants from NIH (AR067885 and AR056702). RB and EMB
are supported by a NIH training grant (AR053459). RWW is supported by a
NIH grant (AR061307). LX is supported by NIH grants (AR048697, AR063650,
and University of Rochester CTSA award UL1 TR000042), a grant from the
National Natural Science Foundation of China (81220108027), and a grant
from the Lymphatic Malformation Institute. EMS is supported by grants from
NIH (P01 AI078907, AR056702 and AR061307).
Competing interests
CTR receives consulting fees and research support from UCB
Pharmaceuticals. The remaining authors declare that they have no
competing interests.
Authors’ contributions
All authors read and approved the final manuscript.
Ethics approval and consent to participate
The studies cited in this publication (ClinicalTrials.gov NCT02680067.
Registered 7 December 2015; ClinicalTrials.gov NCT01098201. Registered 30
March 2010; and ClinicalTrials.gov NCT01083563. Registered 8 March 2010)
obtained ethics approval from the Research Subjects Review Board at the
University of Rochester Medical Center. Informed, written consent to participate
in the studies and consent for publication was obtained from all patients. All
figures and video files in this publication are original for this article.
Author details
1Center for Musculoskeletal Research, University of Rochester School of
Medicine and Dentistry, Rochester, NY, USA. 2Department of Pediatrics,
University of Rochester School of Medicine and Dentistry, Rochester, NY,
USA. 3Department of Pathology and Laboratory Medicine, University of
Rochester School of Medicine and Dentistry, Rochester, NY, USA.
4Department of Biomedical Engineering, University of Rochester School of
Medicine and Dentistry, Rochester, NY, USA. 5Department of Obstetrics and
Gynecology, University of Rochester School of Medicine and Dentistry,
Rochester, NY, USA. 6Department of Urology, University of Rochester School
of Medicine and Dentistry, Rochester, NY, USA. 7Division of Allergy,
Immunology, Rheumatology, Department of Medicine, University of
Rochester School of Medicine and Dentistry, Rochester, NY, USA.
8Department of Neuroscience, University of Rochester School of Medicine
and Dentistry, Rochester, NY, USA. 9University of Rochester Medical Center,
601 Elmwood Avenue, Box 777, Rochester, NY 14642, USA.
References
1. Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid
arthritis: a synopsis. Am J Manag Care. 2014;20(7):S128–35.
2. Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis
Res Ther. 2014;16(3):114.
3. Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C, Pistoia
ML, Liakouli V, Ruscitti P, Ciccia F, et al. Safety and efficacy of intra-articular
anti-tumor necrosis factor alpha agents compared to corticosteroids in a
treat-to-target strategy in patients with inflammatory arthritis and
monoarthritis flare. Int J Immunopathol Pharmacol. 2016;29(2):252–66.
4. Klasen IS, Ladestein RMT, Vandenberg WB, Benner R. Requirements for flare
reactions of joint inflammation induced in mice by cloned Mt4+, Lyt-2– T-
cells. Arthritis Rheum. 1989;32(3):330–7.
Rahimi et al. Arthritis Research & Therapy  (2016) 18:194 Page 7 of 9
5. Lens JW, Vandenberg WB, Vandeputte LBA, Zwarts WA. Flare of antigen-
induced arthritis in mice after intravenous challenge—kinetics of antigen in
the circulation and localization of antigen in the arthritic and noninflamed
joint. Arthritis Rheum. 1986;29(5):665–74.
6. Bingham CO, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU,
Witter JP, Furst DE, Strand CV, Boers M, et al. Developing a standardized
definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special
Interest Group). J Rheumatol. 2009;36(10):2335–41.
7. Benaglio F, Vitolo B, Scarabelli M, Binda E, Bugatti S, Caporali R, Montecucco
C, Manzo A. The draining lymph node in rheumatoid arthritis: current
concepts and research perspectives. Biomed Res Int. 2015;2015:420251.
8. Bouta EM, Li J, Ju Y, Brown EB, Ritchlin CT, Xing L, Schwarz EM. The role of the
lymphatic system in inflammatory-erosive arthritis. Semin Cell Dev Biol. 2015;38:90–7.
9. Semo J, Nicenboim J, Yaniv K. Development of the lymphatic system: new
questions and paradigms. Development. 2016;143(6):924–35.
10. Karpanen T, Alitalo K. Molecular biology and pathology of
lymphangiogenesis. Annu Rev Pathol Mech. 2008;3:367–97.
11. Ionac M, Laskay T, Labahn D, Geisslinger G, Solbach W. Improved technique
for cannulation of the murine thoracic duct: a valuable tool for the
dissection of immune responses. J Immunol Methods. 1997;202(1):35–40.
12. Kaipainen A, Korhonen J, Mustonen T, Vanhinsbergh VWM, Fang GH,
Dumont D, Breitman M, Alitalo K. Expression of the Fms-like tyrosine kinase-
4 gene becomes restricted to lymphatic endothelium during development.
Proc Natl Acad Sci U S A. 1995;92(8):3566–70.
13. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O,
Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is
a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
(vol 15, pg 290, 1996). Embo J. 1996;15(7):1751.
14. Zhou Q, Guo RL, Wood R, Boyce BF, Liang QQ, Wang YJ, Schwarz EM, Xing
LP. Vascular endothelial growth factor C attenuates joint damage in chronic
inflammatory arthritis by accelerating local lymphatic drainage in mice.
Arthritis Rheum. 2011;63(8):2318–28.
15. Zhang Q, Lu Y, Proulx ST, Guo RL, Yao ZQ, Schwarz EM, Boyce BF, Xing LP.
Increased lymphangiogenesis in joints of mice with inflammatory arthritis.
Arthritis Res Ther. 2007;9(6):R118.
16. Guo RL, Zhou Q, Proulx ST, Wood R, Ji RC, Ritchlin CT, Pytowski B, Zhu ZP,
Wang YJ, Schwarz EM, et al. Inhibition of lymphangiogenesis and lymphatic
drainage via vascular endothelial growth factor receptor 3 blockade
increases the severity of inflammation in a mouse model of chronic
inflammatory arthritis. Arthritis Rheum. 2009;60(9):2666–76.
17. Liang QQ, Ju YW, Chen Y, Wang WS, Li JL, Zhang L, Xu H, Wood RW,
Schwarz EM, Boyce BF, et al. Lymphatic endothelial cells efferent to
inflamed joints produce iNOS and inhibit lymphatic vessel contraction and
drainage in TNF-induced arthritis in mice. Arthritis Res Ther. 2016;18:62.
18. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, Tak PP, Schett G,
Zwerina J. Tumour necrosis factor blockade increases lymphangiogenesis in
murine and human arthritic joints. Ann Rheum Dis. 2008;67(11):1610–6.
19. Young A, Koduri G. Extra-articular manifestations and complications of
rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):907–27.
20. Robertson MD, Hart FD, White WF, Nuki G, Boardman PL. Rheumatoid
lymphadenopathy. Ann Rheum Dis. 1968;27(3):253–60.
21. Paulus HE, Machlede H, Peter JB, Goldberg L, Levy J, Pearson CM. Clinical
improvement of rheumatoid-arthritis during prolonged thoracic-duct
lymphocyte drainage. Arthritis Rheum. 1973;16(4):562–3.
22. Paulus HE, Machleder HI, Levine S, Yu DT, MacDonald NS. Lymphocyte
involvement in rheumatoid arthritis. Studies during thoracic duct drainage.
Arthritis Rheum. 1977;20(6):1249–62.
23. Paulus HE, Pearson CM, Peter JB, Stratton JA, Whitehou M, Yu D, Bangert R,
Machlede H, Goldberg L. Effects of removing thoracic-duct lymphocytes
from a patient with severe rheumatoid-arthritis. Arthritis Rheum. 1972;15(1):
122.
24. Paulus HE, Machlede H, Bangert R, Stratton JA, Goldberg L, Whitehou M, Yu
D, Pearson CM. Case report—Thoracic-duct lymphocyte drainage in
rheumatoid-arthritis. Clin Immunol Immunop. 1973;1(2):173–81.
25. Pullinger BD, Florey HW. Proliferation of lymphatics in inflammation. J Path
Bacteriol. 1937;45(1):157–70.
26. Andersson I, Marsal L, Nilsson B, Sjoblom KG, Wollheim FA. Abnormal
axillary lymph nodes in rheumatoid arthritis. Acta Radiol Diagn (Stockh).
1980;21(5):645–9.
27. Olszewski WL, Pazdur J, Kubasiewicz E, Zaleska M, Cooke CJ, Miller NE.
Lymph draining from foot joints in rheumatoid arthritis provides insight
into local cytokine and chemokine production and transport to lymph
nodes. Arthritis Rheum. 2001;44(3):541–9.
28. Kallioma J, Vastamak M. Chronic diffuse oedema of rheumatoid hand—a
sign of local lymphatic involvement. Ann Rheum Dis. 1968;27(2):167.
29. Hart FD. Lymphadenopathy in rheumatic patients. Ann Rheum Dis. 1987;
46(8):645–6.
30. Bohm M, Riemann B, Luger TA, Bonsmann G. Bilateral upper limb
lymphoedema associated with psoriatic arthritis: a case report and review of
the literature. Br J Dermatol. 2000;143(6):1297–301.
31. Sant SM, Tormey VJ, Freyne P, Casey EB. Lymphatic obstruction in
rheumatoid-arthritis. Clin Rheumatol. 1995;14(4):445–50.
32. Mulherin DM, Fitzgerald O, Bresnihan B. Lymphedema of the upper limb in
patients with psoriatic-arthritis. Semin Arthritis Rheum. 1993;22(5):350–6.
33. Kiely PDW, Bland JM, Joseph AEA, Mortimer PS, Bourke BE. Upper-limb
lymphatic function in inflammatory arthritis. J Rheumatol. 1995;22(2):214–7.
34. Proulx ST, Kwok E, You Z, Beck CA, Shealy DJ, Ritchlin CT, Boyce BF, Xing L,
Schwarz EM. MRI and quantification of draining lymph node function in
inflammatory arthritis. Ann N Y Acad Sci. 2007;1117:106–23.
35. Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Calvi LM, Ritchlin
CT, Awad HA, Boyce BF, et al. Elucidating bone marrow edema and
myelopoiesis in murine arthritis using contrast-enhanced magnetic
resonance imaging. Arthritis Rheum. 2008;58(7):2019–29.
36. Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Ritchlin CT, Awad
HA, Boyce BF, Xing L, et al. Longitudinal assessment of synovial, lymph
node, and bone volumes in inflammatory arthritis in mice by in vivo
magnetic resonance imaging and microfocal computed tomography.
Arthritis Rheum. 2007;56(12):4024–37.
37. McQueen FM. Magnetic resonance imaging in early inflammatory arthritis:
what is its role? Rheumatology (Oxford). 2000;39(7):700–6.
38. Li J, Ju YW, Bouta EM, Xing LP, Wood RW, Kuzin I, Bottaro A, Ritchlin
CT, Schwarz EM. Efficacy of B cell depletion therapy for murine joint
arthritis flare is associated with increased lymphatic flow. Arthritis
Rheum. 2013;65(1):130–8.
39. Li J, Ritchlin CT, Sanz I, Bottaro A, Wood R, Xing LP, Schwarz EM. Effective
anti-CD20 therapy for arthritis is associated with B-cell depletion in efferent
lymph nodes and increased lymph and cellular flow in lymphatic vessels
from arthritic joints. Arthritis Rheum. 2011;63(10):S975–6.
40. Zhou Q, Guo RL, Wood R, Proulx ST, Schwarz EM, Boyce BF, Xing LP.
Blockade of lymphangiogenesis and lymphatic draining function enhances
the severity of synovitis in mice with inflammatory-erosive arthritis. Arthritis
Rheum. 2008;58(9):S504.
41. Li J, Kuzin I, Moshkani S, Proulx ST, Xing L, Skrombolas D, Dunn R, Sanz I,
Schwarz EM, Bottaro A. Expanded CD23(+)/CD21(hi) B cells in inflamed
lymph nodes are associated with the onset of inflammatory-erosive arthritis
in TNF-transgenic mice and are targets of anti-CD20 therapy. J Immunol.
2010;184(11):6142–50.
42. Li J, Zhou Q, Wood R, Kuzin I, Bottaro A, Ritchlin C, Xing L, Schwarz E. CD23
+/CD21hi B cell translocation and ipsilateral lymph node collapse is
associated with asymmetric arthritic flare in TNF-Tg mice. Arthritis Res Ther.
2011;13(4):R138.
43. Bouta EM, Wood RW, Brown EB, Rahimi H, Ritchlin CT, Schwarz EM. In vivo
quantification of lymph viscosity and pressure in lymphatic vessels and draining
lymph nodes of arthritic joints in mice. J Physiol. 2014;592(Pt 6):1213–23.
44. Bremander ABI, Petersson IF, Roos E. Validation of the rheumatoid arthritis
outcome score (RAOS)—for the lower extremity. Health Qual Life Outcomes.
2003;1(1):1-11.
45. Huh YM, Kim S, Suh JS, Song HT, Song K, Shin KH. The role of popliteal
lymph nodes in differentiating rheumatoid arthritis from osteoarthritis by
using CE 3D-FSPGR MR imaging: relationship of the inflamed synovial
volume. Korean J Radiol. 2005;6(2):117–24.
46. Gaffney K, Cookson J, Blades S, Coumbe A, Blake D. Quantitative assessment
of the rheumatoid synovial microvascular bed by gadolinium-DTPA
enhanced magnetic resonance imaging. Ann Rheum Dis. 1998;57(3):152–7.
47. Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE,
Lorenzen I. Magnetic resonance imaging-determined synovial membrane
volume as a marker of disease activity and a predictor of progressive joint
destruction in the wrists of patients with rheumatoid arthritis. Arthritis
Rheum. 1999;42(5):918–29.
48. Tan YK, Ostergaard M, Conaghan PG. Imaging tools in rheumatoid arthritis:
ultrasound vs magnetic resonance imaging. Rheumatology (Oxford). 2012;
51 Suppl 7:vii36–42.
Rahimi et al. Arthritis Research & Therapy  (2016) 18:194 Page 8 of 9
49. van de Stadt LA, Bos WH, Meursinge Reynders M, Wieringa H, Turkstra F,
van der Laken CJ, van Schaardenburg D. The value of ultrasonography in
predicting arthritis in auto-antibody positive arthralgia patients: a
prospective cohort study. Arthritis Res Ther. 2010;12(3):R98.
50. Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S,
Bourgeois P, Fautrel B. Power Doppler ultrasound, but not low-field
magnetic resonance imaging, predicts relapse and radiographic disease
progression in rheumatoid arthritis patients with low levels of disease
activity. Arthritis Rheum. 2012;64(1):67–76.
51. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical
and ultrasonographic remission determines different chances of relapse in
early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):172–5.
52. Manzo A, Caporali R, Vitolo B, Alessi S, Benaglio F, Todoerti M, Bugatti S,
Calliada F, Montecucco C. Subclinical remodelling of draining lymph node
structure in early and established rheumatoid arthritis assessed by power
Doppler ultrasonography. Rheumatology (Oxford). 2011;50(8):1395–400.
53. Clavel G, Marchiol-Fournigault C, Renault G, Boissier MC, Fradelizi D, Bessis
N. Ultrasound and Doppler micro-imaging in a model of rheumatoid
arthritis in mice. Ann Rheum Dis. 2008;67(12):1765–72.
54. Hammer HB, Sveinsson M, Kongtorp AK, Kvien TK. A 78-joints ultrasonographic
assessment is associated with clinical assessments and is highly responsive to
improvement in a longitudinal study of patients with rheumatoid arthritis
starting adalimumab treatment. Ann Rheum Dis. 2010;69(7):1349–51.
55. Hartung W, Kellner H, Strunk J, Sattler H, Schmidt WA, Ehrenstein B, Fleck M,
Backhaus M. Development and evaluation of a novel ultrasound score for
large joints in rheumatoid arthritis: one year of experience in daily clinical
practice. Arthritis Care Res (Hoboken). 2011;64(5):675–82.
56. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS,
Ostergaard M. Interobserver agreement in ultrasonography of the finger
and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48(4):955–62.
57. Ju Y, Rahimi H, Li J, Wood RW, Xing L, Schwarz EM. Validation of 3-
dimensional ultrasound versus magnetic resonance imaging quantification
of popliteal lymph node volume as a biomarker of erosive inflammatory
arthritis in mice. Arthritis Rheum. 2012;64(6):2048–50.
58. Bouta EM, Banik PD, Wood RW, Rahimi H, Ritchlin CT, Thiele RG, Schwarz
EM. Validation of power Doppler versus contrast-enhanced magnetic
resonance imaging quantification of joint inflammation in murine
inflammatory arthritis. J Bone Miner Res. 2015;30(4):690–4.
59. Nimura H, Narimiya N, Mitsumori N, Yamazaki Y, Yanaga K, Urashima M.
Infrared ray electronic endoscopy combined with indocyanine green
injection for detection of sentinel nodes of patients with gastric cancer.
Br J Surg. 2004;91(5):575–9.
60. Ito N, Fukuta M, Tokushima T, Nakai K, Ohgi S. Sentinel node navigation
surgery using indocyanine green in patients with lung cancer. Surg Today.
2004;34(7):581–5.
61. Rasmussen JC, Tan IC, Marshall MV, Fife CE, Sevick-Muraca EM. Lymphatic
imaging in humans with near-infrared fluorescence. Curr Opin Biotech.
2009;20(1):74–82.
62. Tan I, Maus E, Rasmussen J, Marshall M, Fife CE, Smith L, Sevick EM. Near-
infrared fluorescence imaging of lymphatics in head and neck
lymphedema. J Nucl Med. 2011;52:101.
63. Tan IC, Maus EA, Rasmussen JC, Marshall MV, Adams KE, Fife CE, Smith LA,
Chan W, Sevick-Muraca EM. Assessment of lymphatic contractile function
after manual lymphatic drainage using near-infrared fluorescence imaging.
Arch Phys Med Rehab. 2011;92(5):756–64.
64. Rasmussen JC, Tan IC, Marshall MV, Adams KE, Kwon S, Fife CE, Maus EA,
Smith LA, Covington KR, Sevick-Muraca EM. Human lymphatic architecture
and dynamic transport imaged using near-infrared fluorescence. Transl
Oncol. 2010;3(6):362–72.
65. Shaw RA, Kotowich S, Eysel HH, Jackson M, Thomson GTD, Mantsch HH.
Arthritis diagnosis based upon the near infrared spectrum of synovial fluid.
Rheumatol Int. 1995;15(4):159–65.
66. Chen WT, Mahmood U, Weissleder R, Tung CH. Arthritis imaging using a near-
infrared fluorescence folate-targeted probe. Arthritis Res Ther. 2005;7(2):R310–7.
67. Hansch A, Frey O, Sauner D, Hilger I, Haas M, Malich A, Brauer R, Kaiser WA.
In vivo imaging of experimental arthritis with near-infrared fluorescence.
Arthritis Rheum. 2004;50(3):961–7.
68. Fischer T, Gemeinhardt I, Wagner S, von Stieglitz D, Schnorr J, Hermann
KGA, Ebert B, Petzelt D, MacDonald R, Licha K, et al. Assessment of
unspecific near-infrared dyes in laser-induced fluorescence imaging of
experimental arthritis. Acad Radiol. 2006;13(1):4–13.
69. Krohn M, Ohrndorf S, Werner SG, Schicke B, Burmester GR, Hamm B,
Backhaus M, Hermann KGA. Near-infrared fluorescence optical imaging in
early rheumatoid arthritis: a comparison to magnetic resonance imaging
and ultrasonography. J Rheumatol. 2015;42(7):1112–8.
Rahimi et al. Arthritis Research & Therapy  (2016) 18:194 Page 9 of 9
